
|Articles|November 17, 2014
NovoTTF and Temozolomide for Glioblastoma
Author(s)Steven A. Toms, MD
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.
Advertisement
Clinical Pearls
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.
- Patients were randomized 2:1 to NovoTTF in combination with temozolomide (n = 210) or standard therapy (n = 105), which included surgery, radiation, and temozolomide.
- Progression-free and overall survival were both enhanced with the addition of NovoTTF.
- Anecdotally, Toms said, NovoTTF has been well-tolerated by patients.
Read more about this novel therapy > >
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































